Home
/
Inmune Bio, Inc.
/
Financials
/
Quarterly
Inmune Bio, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Inmune Bio, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$50.0K
Oct 30, 2025
Q2
2025
Jun 30, 2025
$50.0K
Aug 7, 2025
Q1
2025
Mar 31, 2025
$50.0K
May 8, 2025
Q3
2025
Sep 30, 2024
$14.0K
Oct 30, 2025
Q2
2025
Jun 30, 2024
$14.0K
Aug 7, 2025
Q1
2025
Mar 31, 2024
$14.0K
May 8, 2025
Q3
2024
Sep 30, 2023
$43.0K
Oct 31, 2024
Q2
2024
Jun 30, 2023
$46.0K
Aug 1, 2024
Q1
2024
Mar 31, 2023
$38.0K
May 9, 2024
Q3
2023
Sep 30, 2022
$98.0K
Nov 1, 2023
Q2
2023
Jun 30, 2022
$16.0K
Aug 7, 2023
Q1
2023
Mar 31, 2022
$163.0K
May 3, 2023
Q3
2022
Sep 30, 2021
$14.0K
Nov 2, 2022
Q2
2022
Jun 30, 2021
$4.0K
Aug 3, 2022
Q1
2022
Mar 31, 2021
$4.0K
May 5, 2022
Q2
2019
Jun 30, 2019
$0
Aug 9, 2019
Q1
2019
Mar 31, 2019
$0
May 15, 2019
Q2
2019
Jun 30, 2018
$0
Aug 9, 2019
Q1
2019
Mar 31, 2018
$0
May 15, 2019
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($6.47M)
Oct 30, 2025
Q3
2025
Jun 30, 2025
($24.46M)
Oct 30, 2025
Q2
2025
Jun 30, 2025
($24.46M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($9.74M)
May 8, 2025
Q3
2025
Mar 31, 2025
($9.74M)
Oct 30, 2025
Q2
2025
Mar 31, 2025
($9.74M)
Aug 7, 2025
Q3
2025
Sep 30, 2024
($12.09M)
Oct 30, 2025
Q3
2025
Jun 30, 2024
($9.75M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($9.75M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($11.03M)
May 8, 2025
Q3
2025
Mar 31, 2024
($11.03M)
Oct 30, 2025
Q2
2025
Mar 31, 2024
($11.03M)
Aug 7, 2025
Q3
2024
Sep 30, 2023
($8.56M)
Oct 31, 2024
Q2
2024
Jun 30, 2023
($6.50M)
Aug 1, 2024
Q3
2024
Jun 30, 2023
($6.50M)
Oct 31, 2024
Q3
2024
Mar 31, 2023
($6.54M)
Oct 31, 2024
Q2
2024
Mar 31, 2023
($6.54M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($6.54M)
May 9, 2024
Q3
2023
Sep 30, 2022
($7.73M)
Nov 1, 2023
Q3
2023
Jun 30, 2022
($6.84M)
Nov 1, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($7.43M)
Oct 30, 2025
Q2
2025
Jun 30, 2025
($24.57M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($9.91M)
May 8, 2025
Q3
2025
Sep 30, 2024
($12.29M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($9.87M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($11.02M)
May 8, 2025
Q3
2024
Sep 30, 2023
($8.53M)
Oct 31, 2024
Q2
2024
Jun 30, 2023
($6.41M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($6.42M)
May 9, 2024
Q3
2023
Sep 30, 2022
($7.44M)
Nov 1, 2023
Q2
2023
Jun 30, 2022
($6.39M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($6.48M)
May 3, 2023
Q3
2022
Sep 30, 2021
($9.02M)
Nov 2, 2022
Q2
2022
Jun 30, 2021
($6.55M)
Aug 3, 2022
Q1
2022
Mar 31, 2021
($4.55M)
May 5, 2022
Q3
2021
Sep 30, 2020
($4.82M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($2.11M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($2.09M)
May 5, 2021
Q3
2020
Sep 30, 2019
($3.08M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($428.4K)
Aug 5, 2020